"Nurofen maker deserves $6m fine for false claims, court told", 12 Apr 2016

Nurofen's manufacturer Reckitt Benckiser should be fined $6m for misleading consumers over a range of "targeted" pain products that cost twice as much as its standard painkillers despite having the same active ingredient and effect, the Australian Competition and Consumer Commission (ACCC) has found. In December the federal court found...Reckitt Benckiser...had engaged in "misleading conduct" by representing that its Nurofen Specific Pain products targeted a type or area of pain despite being identical...On Tuesday, lawyers for the ACCC told a federal court...that the company had profited substantially and should be fined accordingly...Reckitt Benckiser said in December that it accepted the federal court’s ruling but denied attempting to deceive customers. “The Nurofen specific-pain range was launched with an intention to help consumers navigate their pain relief options, particularly within the grocery environment where there is no healthcare professional to assist decision-making,” a spokeswoman for Nurofen, Montse Pena, said...